Maintenance therapy for metastatic colorectal cancer
Mené sur 700 patients atteints d'un cancer colorectal métastatique non résécable, cet essai international de phase III évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'ajout d'erlotinib au bévacizumab en traitement d'entretien (durée médiane de suivi : 50 mois)
During the past 15 years, the treatment of metastatic colorectal cancer has greatly improved with the introduction of active cytotoxic drugs, such as irinotecan and oxaliplatin, as well as molecularly targeted drugs, including angiogenesis inhibitors and anti-EGFR monoclonal antibodies. Although in the continuum of care the availability of subsequent lines of treatment with non-cross-resistant drugs, as well as surgery for metastases in selected cases, is relevant for overall survival, treatment efficacy is greatly determined by first-line therapy.
The Lancet Oncology , commentaire, 2014